Primary antibody deficiencies in the context of normal B-cell differentiation
نویسنده
چکیده
Primary antibody deficiencies (PAD) form the largest group of inherited disorders of the immune system. They are characterized by a marked reduction or absence of serum immunglobulins (Ig) and/or a poor response to vaccination due to disturbed B-cell differentiation. PAD can be divided in agammaglobulinemia, Ig class switch recombination defects (formerly called hyper IgM syndromes), and idiopathic hypogammaglobulinemia, including Common Variable Immunodeficiency Disorders (CVIDs). Although, already 17 genes have been identified to be affected in PAD, for many patients a molecular diagnosis is still not made. A molecular diagnosis is of great importance to both patient and family, because it offers a precise cause and it forms the basis of adequate treatment and estimation of prognosis. Furthermore, understanding the molecular defect supports the development of long-term preventive strategies to limit complications and irreversible organ damage and it contributes to treatment compliance and enables genetic counseling. To understand the consequences of PAD gene defects, it is important to find out which crucial processes are disturbed. All PAD gene defects somehow impaired B-cell differentiation and especially the genes affected in the CVID category are involved in many different processes. During the presentation, the effects of genetic defects will be presented in the context of normal B-cell differentiation. In addition, it will be discussed how new technical developments can support understanding of B-cell differentiation and discovering new genetic defects in PAD.
منابع مشابه
Primary Antibody Deficiencies at Queen Rania Children Hospital in Jordan: Single Center Experience
Background: Primary antibody deficiency, the most common primary immunodeficiency disorder, represents a heterogeneous spectrum of conditions caused by a defect in any critical stage of B cell development and is characterized by impaired production of normal amounts of antigen-specific antibodies. Objective: This retrospective study aimed at description and analysis of demographic, clinical, im...
متن کاملB cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease
The B cell is a vital contributor to humoral immunity. The B cell-specific antigen CD20 is expressed during B cell development, starting at the pre-B cell level and persists through B cell differentiation, but is lost during terminal differentiation to plasma cells. Rituximab is a monoclonal antibody that destroys both normal and malignant B cells that have CD20 on their surfaces and is ther...
متن کاملB-cell Development and Differentiation
types of primary immune deficiencies in human subjects. Often symptoms do not appear until the latter part of the first year of life, as passively acquired IgG from the mother decreases to below protective levels. As with the T-cell immune deficiencies, the spectrum of antibody deficiencies is broad, ranging from the most severe type of antibody deficiency with totally absent B cells and serum ...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 8 شماره
صفحات -
تاریخ انتشار 2010